Literature DB >> 28594553

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.

Norihito Shibata1, Katsunori Nagai2, Yoko Morita2, Osamu Ujikawa2, Nobumichi Ohoka1, Takayuki Hattori1, Ryokichi Koyama2, Osamu Sano2, Yasuhiro Imaeda2, Hiroshi Nara2, Nobuo Cho2, Mikihiko Naito1.   

Abstract

Targeted protein degradation using small molecules is a novel strategy for drug development. We have developed hybrid molecules named specific and nongenetic inhibitor of apoptosis protein [IAP]-dependent protein erasers (SNIPERs) that recruit IAP ubiquitin ligases to degrade target proteins. Here, we show novel SNIPERs capable of inducing proteasomal degradation of the androgen receptor (AR). Through derivatization of the SNIPER(AR) molecule at the AR ligand and IAP ligand and linker, we developed 42a (SNIPER(AR)-51), which shows effective protein knockdown activity against AR. Consistent with the degradation of the AR protein, 42a inhibits AR-mediated gene expression and proliferation of androgen-dependent prostate cancer cells. In addition, 42a efficiently induces caspase activation and apoptosis in prostate cancer cells, which was not observed in the cells treated with AR antagonists. These results suggest that SNIPER(AR)s could be leads for an anticancer drug against prostate cancers that exhibit AR-dependent proliferation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28594553     DOI: 10.1021/acs.jmedchem.7b00168

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

Review 1.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

Review 2.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 3.  A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer.

Authors:  James L Mohler
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

Review 4.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

5.  Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Authors:  Xin Han; Lijie Zhao; Weiguo Xiang; Chong Qin; Bukeyan Miao; Donna McEachern; Yu Wang; Hoda Metwally; Lu Wang; Aleksas Matvekas; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2021-08-25       Impact factor: 7.446

6.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

Authors:  Nobumichi Ohoka; Yoko Morita; Katsunori Nagai; Kenichiro Shimokawa; Osamu Ujikawa; Ikuo Fujimori; Masahiro Ito; Youji Hayase; Keiichiro Okuhira; Norihito Shibata; Takayuki Hattori; Tomoya Sameshima; Osamu Sano; Ryokichi Koyama; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

7.  Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.

Authors:  Yali He; Dong-Jin Hwang; Suriyan Ponnusamy; Thirumagal Thiyagarajan; Michael L Mohler; Ramesh Narayanan; Duane D Miller
Journal:  J Med Chem       Date:  2020-10-23       Impact factor: 7.446

8.  Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation.

Authors:  Kenichiro Shimokawa; Norihito Shibata; Tomoya Sameshima; Naoki Miyamoto; Osamu Ujikawa; Hiroshi Nara; Nobumichi Ohoka; Takayuki Hattori; Nobuo Cho; Mikihiko Naito
Journal:  ACS Med Chem Lett       Date:  2017-09-14       Impact factor: 4.345

9.  Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

Authors:  Weiguo Xiang; Lijie Zhao; Xin Han; Chong Qin; Bukeyan Miao; Donna McEachern; Yu Wang; Hoda Metwally; Paul D Kirchhoff; Lu Wang; Aleksas Matvekas; Miao He; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2021-09-02       Impact factor: 7.446

Review 10.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.